List of Roman birth and childhood deities

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, November 1, 2023
Compensated emancipation, Employment, Pharmaceutical industry, Financial adviser, List of Roman birth and childhood deities

CLEVELAND, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company.

Key Points: 
  • CLEVELAND, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • On October 31, 2023, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 59,600 restricted shares of Abeona common stock.
  • One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.

Luxury fragrance house Electimuss London launches Vanilla Edesia perfume

Retrieved on: 
Tuesday, October 17, 2023
Collection, Ancient Rome, Perfume, Heart, Vanilla, Music, London, NERO, Flower, Woman, Heliotrope, Pleasure, List of Roman birth and childhood deities

LONDON, Oct. 17, 2023 /PRNewswire-PRWeb/ -- Niche perfume brand Electimuss London is renowned for its luxury perfumes inspired by Ancient Rome. The latest perfume Vanilla Edesia has been created in collaboration with master perfumer CIcile Zarokian and launches into the NERO collection.

Key Points: 
  • Niche perfume brand Electimuss London is renowned for its luxury perfumes inspired by Ancient Rome.
  • The latest perfume Vanilla Edesia has been created in collaboration with master perfumer CIcile Zarokian and launches into the NERO collection.
  • LONDON, Oct. 17, 2023 /PRNewswire-PRWeb/ -- Niche perfume brand Electimuss London is renowned for its luxury perfumes inspired by Ancient Rome.
  • The latest perfume Vanilla Edesia has been created in collaboration with master perfumer CIcile Zarokian and launches into the NERO collection.

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

Retrieved on: 
Wednesday, August 30, 2023
Biologics license application, Indiana University, RDEB, Regenerative Medicine Advanced Therapy, Concha bullosa, Chemistry, Regenerative medicine, Patient, Agency, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Safety, Pharmaceutical industry, List of Roman birth and childhood deities

At the meeting, Abeona reached alignment with the FDA that the EB-101 clinical efficacy and safety data appear adequate to support a BLA submission.

Key Points: 
  • At the meeting, Abeona reached alignment with the FDA that the EB-101 clinical efficacy and safety data appear adequate to support a BLA submission.
  • The Agency also agreed that retroviral vector manufactured at Abeona and Indiana University appear comparable based on the data that Abeona provided in its briefing book.
  • The FDA requested that Abeona include within its BLA submission additional background and data supporting the scientific rationale underlying its EB-101 potency and identity assays so that they can be fully evaluated by the Agency post-submission.
  • “We are pleased with the outcome of the pre-BLA meeting for EB-101 and believe that we have aligned with the FDA on what is needed for our upcoming BLA submission,” said Vish Seshadri, Chief Executive Officer of Abeona.

Abeona Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Society, Gene, ISID, CMC, New Drug Application, History, AAV, Chemistry, RVV, Investment, International Society for Stem Cell Research, Ophthalmology, Cell, Research, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Safety, BLA, Process performance qualification protocol, Food, SPD, Cryptocurrency, Pharmaceutical industry, RDEB, List of Roman birth and childhood deities

CLEVELAND, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives.

Key Points: 
  • CLEVELAND, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives.
  • Abeona anticipates submitting the BLA in the third quarter of 2023.
  • License and other revenues in the second quarter of 2023 were $3.5 million, compared to $1.0 million in the second quarter of 2022.
  • Abeona Therapeutics will host a conference call and webcast today, August 8, 2023, at 8:30 a.m.

Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Friday, July 7, 2023
Attention, PRV, Park Avenue, Enterprise file synchronization and sharing, Sale, Health, Prospectus, Equity capital markets, S-3, 4th floor, Form, Security (finance), FDA, BLA, Pharmaceutical industry, List of Roman birth and childhood deities

CLEVELAND, July 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered direct offering for total gross proceeds of $25 million, before deducting the placement agents’ fees and other offering expenses.

Key Points: 
  • CLEVELAND, July 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered direct offering for total gross proceeds of $25 million, before deducting the placement agents’ fees and other offering expenses.
  • “Our existing institutional investors have shown their confidence in Abeona by participating in this registered direct offering without discounts or warrant coverage,” said Vish Seshadri, Chief Executive Officer of Abeona.
  • The offering was led by Nantahala Capital Management, LLC and included participation by Adage Capital Partners LP and two other existing investors.
  • The securities described above were offered pursuant to a shelf registration statement on Form S-3 (File No.

Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, July 3, 2023
Attention, PRV, Park Avenue, Enterprise file synchronization and sharing, Sale, Prospectus, Equity capital markets, 4th floor, Form, Security (finance), FDA, BLA, List of Roman birth and childhood deities

The closing of the offering is expected to occur on or about July 6, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about July 6, 2023, subject to the satisfaction of customary closing conditions.
  • The offering was led by Nantahala Capital Management, LLC and included participation by Adage Capital Partners LP and two other existing institutional investors.
  • Cantor Fitzgerald & Co. is acting as the sole lead-placement agent for the offering.
  • The gross proceeds to Abeona from this offering are expected to be approximately $25 million, before deducting the placement agent’s fees and other offering expenses.

Chobani Continues to Invest in Combatting Child Hunger with Launch of Raspberry Lemonade Greek Yogurt Child Hunger Batch

Retrieved on: 
Tuesday, June 27, 2023
Kwashiorkor, Refugee, Partnership, Nutrition, Food, Indianapolis Community Food Access Coalition, Consumer, Malnutrition, GMO, Chobani, 24 Hour Road Race to End Child Hunger, Child, School, Operation Homefront, Hospital, White House conference, Risk, Yogurt, Venezuela, Strained yogurt, Probiotic, Conference, FAIR, Soft drink, Pharmaceutical industry, List of Roman birth and childhood deities, Health, Hunger

NEW BERLIN, N.Y., June 27, 2023 /PRNewswire/ -- Chobani today announced another step in its efforts to combat child hunger with the release of a Raspberry Lemonade Greek Yogurt 4-pack. The latest in its impact batches tied to charitable efforts, Chobani® Child Hunger Batch supports Edesia, a global nonprofit that produces specialized food designed to combat severe malnutrition.

Key Points: 
  • NEW BERLIN, N.Y., June 27, 2023 /PRNewswire/ -- Chobani today announced another step in its efforts to combat child hunger with the release of a Raspberry Lemonade Greek Yogurt 4-pack.
  • The Chobani Child Hunger Batch is a layered lemon Greek Yogurt with real raspberry on the bottom, a delicious raspberry lemonade flavor reminiscent of childhood summers.
  • Chobani Child Hunger Batch is sold nationwide in 5.3oz 4-packs at a listed suggested retail price of $4.99.
  • Chobani continues to use food as a force for good by expanding its line of products tied to charitable causes, with the Child Hunger Batch joining Hero Batch and Refugee Support Batch .

Abeona Therapeutics Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
PRV, Gene, Stargardt disease, Priority review, ISID, Drug discovery, Stargardt, Concha bullosa, AAV, Investment, International Society for Infectious Diseases, ADOA, Cell, Webcast, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, BLA, Society, Food, Pharmaceutical industry, Cryptocurrency, RDEB, List of Roman birth and childhood deities

CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives.

Key Points: 
  • Continues to make progress toward Biologics License Application (BLA) submission for EB-101 in late-2Q/early-3Q 2023; submitted request for pre-BLA meeting
    Reiterates cash runway guidance into 3Q 2024, beyond anticipated timing for EB-101 BLA potential approval
    CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives.
  • The Company has been granted pre-Investigational New Drug Application meetings for two of its programs to take place in the second quarter of 2023.
  • “Our operating cash burn for the first quarter of 2023 and projected operating cash burn for the second quarter of 2023 include BLA submission and personnel costs, which we expect will be substantially lower in the second half of 2023,” said Joe Vazzano, Chief Financial Officer of Abeona.
  • License and other revenues in the first quarter of 2023 were nil, compared to $0.3 million in the first quarter of 2022.

Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 29, 2023
Biologics license application, CLN1, Business development, PRV, Priority review, ISID, Drug discovery, Rett syndrome, Stargardt, Bristol Myers Squibb, Holocene, Concha bullosa, AAV, MSHS, Rare, Dermatology, Eye, Orphanet Journal of Rare Diseases, Patient, Investment, International Society for Infectious Diseases, Ophthalmology, ADOA, Congress, Retinoschisis, FDA, Research, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Global marketing, BLA, Food, Wound healing, Medical imaging, Pharmaceutical industry, Vaccine, Cryptocurrency, Stargardt disease, RDEB, List of Roman birth and childhood deities

NEW YORK and CLEVELAND, March 29, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2022 and provided an update on progress toward achieving key corporate objectives. The Company will host a conference call and webcast today, March 29, 2023, at 8:30 a.m. ET, to discuss its financial results and business update.

Key Points: 
  • ET, to discuss its financial results and business update.
  • The Company currently plans to submit a BLA for EB-101 in late second quarter to early third quarter of 2023.
  • Abeona appointed Dmitriy Grachev, M.D., Ph.D., as Chief Medical Officer and Madhav Vasanthavada, Ph.D., M.B.A. as Vice President, Business Development.
  • Abeona Therapeutics will host a conference call and webcast today, March 29, 2023, at 8:30 a.m.

Abeona Therapeutics Announces New Employee Inducement Grants

Retrieved on: 
Friday, March 24, 2023
Employment, Pharmaceutical industry, List of Roman birth and childhood deities

NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona.

Key Points: 
  • NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona.
  • On March 23, 2023, Abeona granted restricted stock equity awards to six employees as an inducement for them to accept employment, which equity awards relate to, in the aggregate, up to 131,750 restricted shares of Abeona common stock.
  • One-quarter (1/4) of the shares subject to such restricted stock awards vesting on the first anniversary of the grant date, conditioned upon each employee’s continued employment on the vesting date(s).
  • The inducement grants were approved by Abeona’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).